Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic”

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic” Publisher Pubmed

Shakshouk H^{1, 2} ; Daneshpazhooh M³ ; Murrell DF⁴ ; Lehman JS¹

Source: Journal of the American Academy of Dermatology Published:2021

Abstract

[No abstract available]

Related Docs

View other Related Docs

1. A Systematic Review on Efficacy, Safety, and Treatment-Durability of Low-Dose Rituximab for the Treatment of Pemphigus: Special Focus on Covid-19 Pandemic Concerns, Immunopharmacology and Immunotoxicology (2021)

2. Treatment Concerns for Bullous Pemphigoid in the Covid-19 Pandemic Era, Dermatologic Therapy (2020)

3. Covid-19: The Experience From Iran, Clinics in Dermatology (2021)

Experts (# of related papers)

View all Related Experts

Maryam Daneshpajooh (5)

Hamid Reza Mahmoodi (4)

Other Related Docs

4. Covid Vaccination in Patients Under Treatment With Rituximab: A Presentation of Two Cases From Iran and a Review of the Current Knowledge With a Specific Focus on Pemphigus, Dermatologic Therapy (2022)

5. The Efficacy of Rituximab in Patients With Mucous Membrane Pemphigoid, Journal of Dermatological Treatment (2022)

6. Adverse Outcome and Severity of Covid-19 in Patients With Autoimmune Bullous Diseases: A Historical Cohort Study, Dermatologic Therapy (2022)

Style	Citing Format
MLA	Shakshouk H, et al.. "Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic”." Journal of the American Academy of Dermatology, vol. 84, no. 1, 2021, pp. e61-e62.
APA	Shakshouk H, Daneshpazhooh M, Murrell DF, Lehman JS (2021). Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic”. Journal of the American Academy of Dermatology, 84(1), e61-e62.
Chicago	Shakshouk H, Daneshpazhooh M, Murrell DF, Lehman JS. "Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic”." Journal of the American Academy of Dermatology 84, no. 1 (2021): e61-e62.
Harvard	Shakshouk H et al. (2021) 'Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic”', Journal of the American Academy of Dermatology, 84(1), pp. e61-e62.
Vancouver	Shakshouk H, Daneshpazhooh M, Murrell DF, Lehman JS. Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic”. Journal of the American Academy of Dermatology. 2021;84(1):e61-e62.
BibTex	@article{ author = {Shakshouk H and Daneshpazhooh M and Murrell DF and Lehman JS}, title = {Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic”}, journal = {Journal of the American Academy of Dermatology}, volume = {84}, number = {1}, pages = {e61-e62}, year = {2021} }
RIS	TY - JOUR AU - Shakshouk H AU - Daneshpazhooh M AU - Murrell DF AU - Lehman JS TI - Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic” JO - Journal of the American Academy of Dermatology VL - 84 IS - 1 SP - e61 EP - e62 PY - 2021 ER -